Q-omics provides the consensus-scored MIR606 profile across patient tissues and cancer cell-line models. MIR606 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR606 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, MIR606 RNA expression shows 9,229 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, UCEC, and LSCC as cancer lineages where MIR606 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR606 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR606 survival associations across molecular data types. MIR606 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR606 RNA expression–survival associations across cancer types. High MIR606 expression shows unfavorable associations in KIRC, DLBC, SKCM, ACC, LIHC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR606 RNA expression.
This table summarizes MIR606 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR606. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR606 shows lower tumor expression in LUSC and higher tumor expression in UCEC. The UCEC box plot shows higher MIR606 RNA expression in tumor versus normal tissue (log2 FC = +1.565, t-test p = .038).
This table shows molecular features associated with MIR606 in patient tissues and cancer cell lines. In patient samples, MIR606 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
